Skip to main content

Table 2 The correlation between OS and clinicopathological factors assessable prior to chemotherapy in all patients

From: Prognostic value of tumor-infiltrating CD163+macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment

Variables (n = 68)

Cut off level

Number of patients

HR

95%CI

p

Sex male/female

 

56/12

0.671

0.318- 1.413

0.293

Age < 70 years/ ≥ 70 years/

 

52/16

1.211

0.592- 2.474

0.600

Performance status 0/1

 

57/11

1.503

0.665- 3.394

0.327

Histological differentiation intestinal /diffuse

 

41/27

1.859

0.927- 3.727

0.081

Haematogenous +/-

 

29/39

1.742

0.938- 3.230

0.078

Lymphogenous +/-

 

47/21

0.568

0.302- 1.068

0.079

Yoshida classification category 1/2

 

23/45

2.595

1.261–5.341

0.011

Multiple non-curative factors +/-

 

39/29

1.707

0.921–3.164

0.089

Albumin (g/dl) low/high

3.8

37/31

0.447

0.233- 0.853

0.015

CEA (ng/ml) low/high

5

38/30

0.719

0.384- 1.343

0.301

CA19-9 (U/ml) low/high

37

43/25

1.392

0.745- 2.598

0.299

NLR low/high

3.1

31/37

2.142

1.134- 4.047

0.018

PLR low/high

189

33/35

0.092

0.914- 3.207

0.092

LMR low/high

3.7

32/36

0.479

0.257- 0.892

0.020

CD4+ lymphocyte /Hpf low/high

15

29/39

0.610

0.329–1.129

0.116

CD8+ lymphocyte /Hpf low/high

34

54/14

0.324

0.126–0.832

0.019

Foxp3+ lymphocyte /Hpf low/high

9

47/21

1.671

0.886- 3.150

0.112

CD68+ macrophage /Hpf low/high

28

36/32

1.593

0.856- 2.964

0.142

CD163+ macrophage /Hpf low/high

35

28/40

3.459

1.725–6.937

0.001

  1. NLR Neutrophil to lymphocyte ratio, PLR Platelet to lymphocyte ratio, LMR Lymphocyte to monocyte ratio